2024 saw continued R&D focus, deepening net loss (PLN -11.2m), and major equity raises to fund operations. Commercialization of Genomtec ID and OncoSNAAT is targeted via M&A or licensing, with sufficient liquidity for at least 12 months.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.